edward garon md, expounds on the new fda approval of erlotinib ramuciramab in egfr positive ansclc
Published 4 years ago • 46 plays • Length 2:39Download video MP4
Download video MP3
Similar videos
-
2:06
edward garon, md, examines the adaura clinical study regarding adjuvant treatment in nsclc
-
2:50
edward garon, md, examines dual immunotherapy approach in the cityscape trial
-
1:04
edward garon, md, discusses length of use when combining i-o with chemotherapy in 1st line nsclc
-
0:56
dr. garon on potential for immunotherapy in egfr nsclc
-
0:47
dr. edward garon on the future of combination treatments in lung cancer
-
4:20
erlotinib plus ramucirumab for egfr mutant lung cancer
-
6:41
relay: erlotinib with ramucirumab for egfr nsclc
-
6:07
erlotinib for neoadjuvant treatment of egfr nsclc
-
37:47
why the gi doctor may hold the answers to your lung disease
-
53:16
mitochondrial myopathy: are you out of breath?
-
58:57
taking care of your aorta 10/15/18 (virtual medical symposium series)
-
1:10
dr. garon on the role of trastuzumab deruxtecan in lung cancer
-
0:58
pulmonary fibrosis awareness month: prof dan chambers
-
3:26
nejm 医学前沿 adds pulmonary disease to content library
-
16:43
radiant and select: is adjuvant erlotinib effective in early-stage lung cancer?
-
1:43
erlotinib prevent disease recurrence in early stage egfr positive nsclc patients?
-
1:17
clinical respiratory medicine, 4th edition
-
2:04
the spiromics study
-
0:37
advise of a specilist - lung tumors
-
2:17
world first in asthma research
-
3:11
technological advances in pulmonary medicine—reda girgis, md
-
1:49
30 reasons for research: brennen and matthew